Home | Publications | Research (R&D) | Pipeline place holder
place holder place holder

Pipeline

Genzyme Corporation Product Pipeline Analysis


Publication Date   August 2008
Publisher   Global Markets Direct
Product Type   Report
Pages   66
ISBN Number   not applicable
Product Code   GMD645
Ask a question about this product?

Price £505.00

approximately: $753 | €602

Summary


This report is an insightful source for data, analysis and strategic insights into a Genzyme Corporation's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

  • Details of development stage by sector and equipment type.
  • Pipeline products grouped by therapy area, development stage and trial phase.
  • Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
  • Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
  • Product updates covering estimated approval dates and estimated launch dates.
  • Descriptions of novel technologies relating to pipeline products of the company.
  • Patents and patent applications covered for the product.
  • News updates on key events relating to the product and its development.

Reasons to buy

  • A single source to fulfill competitor information relating to products in development.
  • Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

  • Access clinical trial information to map trial results and plan targeted marketing activities.
  • Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
  • Identification of potential investment opportunities.
  • Build up knowledge base for potential distribution and marketing partners.
  • Helps avoid patent infringement.
  • Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Content


  • 1 List of Tables
    • 1.2 List of Figures
  • 2 Company Snapshot
    • 2.1 Key Information
    • 2.2 Company Overview
    • 2.3 Financial Performance
    • 2.4 Industry Outlook - Orthopedic Devices
    • 2.5 Industry Outlook - In Vitro Diagnostics
  • 3 Business Description
    • 3.1 Business Overview
    • 3.2 Major Products and Services
      • 3.2.1 Overview
  • 4 History
  • 5 Competitors
  • 6 Key Employees
  • 7 Key Employee Biographies
  • 8 Company Statement
  • 9 Locations And Subsidiaries
    • 9.1 Head Office
    • 9.2 Other Locations & Subsidiaries
  • 10 Recent Developments
    • 10.1 Financial Announcements
      • 10.1.1 Jul 23, 2008: Genzyme Reports 2Q 2008 Results
      • 10.1.2 Apr 23, 2008: Genzyme Declares Q1 2008 Results
      • 10.1.3 Feb 13, 2008: Genzyme Declares Q4 2007 Results
      • 10.1.4 Oct 24, 2007: Genzyme Declares Q3 2007 Results
      • 10.1.5 Jul 25, 2007: Genzyme Declares Q2 2007 Results
    • 10.2 Legal and Regulatory
      • 10.2.1 Aug 09, 2007: Genzyme Settles Lawsuit Brought By Shareholders
    • 10.3 Product News
      • 10.3.1 Apr 14, 2008: Genzyme Genetics Announces Launch Of Carrier Testing And Prenatal Diagnosis For Spinal Muscular Atrophy
      • 10.3.2 Dec 19, 2007: Genzyme Receives European CE Mark For Single-Treatment Synvisc-One
      • 10.3.3 Nov 13, 2007: Genzyme Corporation Receives FDA Response Letter On Synvisc-One Approval In US To Be Delayed
      • 10.3.4 Nov 13, 2007: Genzyme Receives FDA Response Letter On Synvisc-One
      • 10.3.5 Jul 05, 2007: Genzyme Announces Results Of Clinical Trial For Hylastan
      • 10.3.6 Jul 05, 2007: Genzyme Arthritis Treatment Misses Goal In Pivotal Trial; Company Will Pursue Alternative Strategy
    • 10.4 Product Approvals
      • 10.4.1 Dec 19, 2007: Genzyme Receives European CE Mark For Single-Treatment Synvisc-One
    • 10.5 Clinical Trials
      • 10.5.1 Jul 05, 2007: Genzyme Announces Results Of Clinical Trial For Hylastan
      • 10.5.2 Jul 05, 2007: Genzyme Arthritis Treatment Misses Goal In Pivotal Trial; Company Will Pursue Alternative Strategy
  • 11 Genzyme Corporation Pipeline Products
    • 11.1 Genzyme Corporation Product Pipeline Analysis
      • 11.1.1 Genzyme Corporation Pipeline Products By Equipment Type
      • 11.1.2 Genzyme Corporation Pipeline Products By Development Stage
      • 11.1.3 Genzyme Corporation Pipeline Products By Therapy Area
      • 11.1.4 Genzyme Corporation Pipeline Products By Clinical Trials
      • 11.1.5 Genzyme Corporation Pipeline Products By News Summary
    • 11.2 Synvisc-One
      • 11.2.1 Product Description
      • 11.2.2 Product Status
      • 11.2.3 Clinical Trials
      • 11.2.4 Product Milestone
    • 11.3 Next Generation Synvisc (hylan G-F 20)
      • 11.3.1 Product Description
      • 11.3.2 Product Status
      • 11.3.3 Clinical Trials
      • 11.3.4 Product Milestone
    • 11.4 Carticel II
      • 11.4.1 Product Description
      • 11.4.2 Product Status
      • 11.4.3 Clinical Trials
    • 11.5 Hylastan
      • 11.5.1 Product Description
      • 11.5.2 Product Status
      • 11.5.3 Clinical Trials
      • 11.5.4 Product Milestone
    • 11.6 Sepragel Ortho
      • 11.6.1 Product Description
      • 11.6.2 Product Status
    • 11.7 Third generation cartilage repair
      • 11.7.1 Product Description
      • 11.7.2 Product Status
    • 11.8 Sepraspray adhesion barrier
      • 11.8.1 Product Description
      • 11.8.2 Product Status
      • 11.8.3 Clinical Trials
    • 11.9 Novel tests for new targeted therapies in hematologic malignancy
      • 11.9.1 Product Description
      • 11.9.2 Product Status
    • 11.10 Candida Rapid Test
      • 11.10.1 Product Description
      • 11.10.2 Product Status
    • 11.11 CLIA waived Flu A & B rapid test
      • 11.11.1 Product Description
      • 11.11.2 Product Status
    • 11.12 C. difficile toxin A & B rapid test
      • 11.12.1 Product Description
      • 11.12.2 Product Status
    • 11.13 Adenovirus rapid test
      • 11.13.1 Product Description
      • 11.13.2 Product Status
    • 11.14 Hemoglobin A1c-diabetes
      • 11.14.1 Product Description
      • 11.14.2 Product Status
    • 11.15 KIM-1 - renal
      • 11.15.1 Product Description
      • 11.15.2 Product Status
    • 11.16 Cystatin C renal
      • 11.16.1 Product Description
      • 11.16.2 Product Status
  • 12 Appendix
    • 12.1 Methodology
      • 12.1.1 Coverage
      • 12.1.2 Secondary Research
      • 12.1.3 Primary Research
      • 12.1.4 Expert Panel Validation
    • 12.2 Contact Us
    • 12.3 About Global Markets Direct
    • 12.4 Disclaimer
  • 1 List of Tables
    • Table 1: Genzyme Corporation,Key Facts
    • Table 2: Genzyme Corporation, Key Employees,
    • Table 3: Genzyme Corporation, Subsidiaries
    • Table 4: Genzyme Corporation Pipeline Products by Equipment Type
    • Table 5: Genzyme Corporation Pipeline Products By Development Stage
    • Table 6: Genzyme Corporation Pipeline Products By Therapy Area
    • Table 7: Genzyme Corporation Pipeline Products By Clinical Trials
    • Table 8: Genzyme Corporation Pipeline Products By News Summaries
    • 1.2 List of Figures
    • Figure 1: Genzyme Corporation Pipeline Products By Equipment Type
    • Figure 2: Genzyme Corporation Pipeline Products By Equipment Type
    • Figure 3: Genzyme Corporation Pipeline Products By Development Stage
    • Figure 4: Genzyme Corporation Pipeline Products By News Summary
    • Figure 5: Global Markets Direct Methodology